Open AccessAnalogy of Kaba Suram with COVID-19 Symptoms - A Siddha Literature Review
Author(s) -
Susila Rathinam,
Muthiah Kannan,
P Sathiyarajeswaran,
Kavitha Tamilarasan,
E. Selvarajan,
Usha Ayyasamy
Publication year - 2020
Publication title -
international journal of ayurvedic medicine
Language(s) - English
Resource type - Journals
ISSN - 0976-5921
DOI - 10.47552/ijam.v11i4.1674
Subject(s) - siddha , medicine , traditional medicine , alternative medicine , covid-19 , pandemic , disease , pathology , infectious disease (medical specialty)
Kaba Suram (phlegmatic fever) is one among the 64 types of Suram (Pyrexia/fever), its synonyms, causes, pathology and characteristics have been mentioned crystal clear in Siddha literature. Its clinical features have been mentioned in few literatures such as Theran karisal, Suravagadam, Yugi chinthamani etc., which are almost similar to each other. The present day pandemic disease COVID-19 which still lacks specific drug towards its management or prophylaxis has become the spectrum of research focus in current scenario. Upon keen understanding of the Siddha literature the signs and symptoms of Kaba Suram fall in line with COVID-19 and a few other flu like illnesses. Therefore, the herbal decoction Kaba Sura Kudineer (KSK) indicated for the management of Kaba Suram has been recommended by the Siddha research community towards an integrated approach in tackling this worldwide emergency. The current scientific community demands evidence based explanation to understand the concept of Siddha system of medicine and necessitates International standards to reassure the efficacy of Siddha medicine. In this aspect, this review is aimed at evaluating all the available informations on Kaba Suram in Siddha literature and pathophysiology of COVID-19 and to interpret the search results in terms of pathophysiology of Kaba Suram based on Mukkutram theory. This effort would therefore enable the Siddha research community to opt for effective Siddha medicines to manage the present pandemic situation.